Show simple item record

dc.contributor.authorEarl, H
dc.contributor.authorHiller, L
dc.contributor.authorVallier, L
dc.contributor.authorLoi, S
dc.contributor.authorHowe, D
dc.contributor.authorHiggins, H
dc.contributor.authorMcAdam, K
dc.contributor.authorHughes-Davies, L
dc.contributor.authorHarnett, A
dc.contributor.authorAh-See, L
dc.contributor.authorSimcock, R
dc.contributor.authorRea, D
dc.contributor.authorMansi, J
dc.contributor.authorAbraham, J
dc.contributor.authorCaldas, C
dc.contributor.authorHulme, C
dc.contributor.authorMiles, D
dc.contributor.authorWardley, Andrew M
dc.contributor.authorCameron, D
dc.contributor.authorDunn, J
dc.date.accessioned2019-03-29T14:22:33Z
dc.date.available2019-03-29T14:22:33Z
dc.date.issued2018en
dc.identifier.citationEarl H, Hiller L, Vallier A, Loi S, Howe D, Higgins H, et al. PERSEPHONE: a randomised phase 3 non-inferiority trial of 6 versus 12 months (m) of adjuvant trastuzumab in patients with HER2 positive (+) early breast cancer (EBC). Br J Cancer. 2018;119(11):43.en
dc.identifier.urihttp://hdl.handle.net/10541/621685
dc.language.isoenen
dc.titlePERSEPHONE: a randomised phase 3 non-inferiority trial of 6 versus 12 months (m) of adjuvant trastuzumab in patients with HER2 positive (+) early breast cancer (EBC)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMCRC Biobank, The Christie NHS Foundation Trust, Manchesteren
dc.identifier.journalBritish Journal of Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record